Sponsors Urged to Drop "QES Everywhere" Default in Global Trials, Adopt Four-Dimension Consent Framework

Clinical trial sponsors should stop treating qualified electronic signatures (QES) as a global default for informed consent, according to a practical framework developed from experience across dozens of multinational protocols. The guidance argues that signature modality is a country-by-country — and sometimes site-by-site — decision, and that applying the highest compliance bar uniformly is both expensive and operationally counterproductive.

Under eIDAS in the European Union, QES carries full legal equivalence to a wet-ink signature, backed by identity verification through a qualified trust service provider (QTSP) rather than a site staff member checking an ID at the door. That legal weight drives some sponsors to deploy it everywhere a study runs. But the framework's authors warn that getting the decision wrong in either direction creates real problems: too little QES risks a regulatory finding, while too much adds cost, training burden and friction for participants who did not need it.

Four Dimensions, Weighted Equally

The framework evaluates signature choice across four dimensions of equal weight, with one exception: a hard "must-have" in any single dimension may settle the decision on its own.

Country requirements. Sponsors should first determine whether QES is mandated, preferred or simply accepted in each jurisdiction. A mandate overrides every other consideration. Where QES is merely preferred, the decision tilts toward it. Where AES is accepted, the analysis does not end there — regulatory bodies may still lean toward, prefer or informally expect QES in practice, so sponsors should evaluate local authority expectations alongside the letter of the requirement.

Study risk profile. High-risk indications, protocols likely to be inspected, and ultra-rare populations where losing a single participant is especially costly all favor QES's third-party-verified identity foundation, which provides a high-quality audit trail if someone later claims a different person signed consent. Where the risk of an identity dispute is very low, AES may be more practical, reducing costs and avoiding delays before a participant's first visit.

Participant population. This is where the framework's authors say good intentions collide with operational realities. QES identity verification typically requires a facial recognition scan matched to government-issued identification, performed inside an app on the participant's phone. It adds roughly 2-5 minutes of participant-facing overhead before the consent document is even seen, and some participants will struggle to complete it. The authors cite remote or low-literacy populations without reliable access to identification documents, and patients with physical conditions that make camera use difficult — for example, patients with Parkinson's disease (搜索)搜索该疾病 in a trial may struggle to hold a phone still enough to pass the facial scan. ID documents are not uniform either: not every eligible person in a country holds a passport, so a QTSP that accepts only passports creates an access gap.

Operational feasibility. The final dimension asks whether selected sites are set up for QES. Site staff need training on an authentication handoff many have never performed, participants may need help installing and launching the QTSP app, and teams have limits on how many technologies and processes they can manage at once.

None of the four dimensions is meant to be evaluated in isolation, and apart from a hard mandate, none should carry more weight than the others. The authors describe "QES everywhere" and "QES nowhere but where it's mandated" as shortcuts that skip the actual work.

From Framework to Site-Level Execution

The framework only holds up operationally if it is documented before enrollment starts. The guidance recommends four steps.

First, document the country-level decision for every country in the study, recording which signature method applies and why, and treating that document as a decision matrix rather than a paragraph buried in the protocol. Regulatory affairs and clinical operations should own it jointly, since the decision sits at the intersection of both functions.

Second, translate the decision into site-level instructions — a one-page job aid that walks coordinators through exactly how to execute their site's designated signature method, step by step and in plain language. Coordinators are not deciding between AES and QES at the point of care; that call has already been made upstream, and what they need is clarity on carrying out the selected approach correctly every time.

Third, configure the technology to enforce the correct modality for each country and population rather than relying on training alone. Where the system can auto-route participants to the correct modality based on country and block coordinators from attempting the wrong one, that is ideal — but where it is not possible, staff must be trained on exceptions. A documented wet-ink fallback should be established for participants who cannot complete ID verification, since in a large enough study some participants will inevitably encounter this issue.

Fourth, monitor for failures. QES does not work for every ID document, and any participant can run into verification issues. The fallback must be defined before enrollment begins so a coordinator does not have to improvise during a live consent visit.

Common Pitfalls and the Limits of Standardization

The most common mistake, according to the guidance, is applying QES uniformly without country-by-country evaluation — treating the highest compliance bar as the safest default when AES is legally sufficient in most jurisdictions. A second is underestimating site training: coordinators need explicit, hands-on preparation for a QTSP handoff that is genuinely unfamiliar, not a slide deck seen once during startup. Third, sponsors often fail to plan for participants who cannot complete identity verification, leaving sites to determine next steps during a live consent visit when the consequences of delay or confusion are greatest. Finally, QES should be treated as a strategic decision rather than a plug-in feature.

A parallel analysis of cross-border QES operationalization reaches similar conclusions, noting that there is no single globally accepted standard for electronic signatures in clinical trials. Regulatory frameworks may appear aligned on paper, but requirements diverge across countries, regions and even sites, so what qualifies as compliant in one jurisdiction may introduce risk in another — particularly for high-stakes processes such as informed consent. National authorities retain discretion in how recognized tiers of electronic signatures are applied, producing differing expectations for acceptable signature types.

That variability means a single global trial may incorporate fully electronic signatures in some regions, hybrid or print-based formats in others, and traditional paper-based consent where necessary. These differences are described not as exceptions to be managed but as inherent characteristics of multinational study design; efforts to enforce uniformity can introduce delays, increase non-compliance risk, or create unnecessary burden for sites and participants.

Higher-assurance methods such as QES provide maximum legal certainty by verifying signer identity and protecting document integrity, typically through a multi-step workflow: participants validate government-issued identification or undergo biometric checks, then sign in a secure, certified environment, after which the document is cryptographically sealed and time-stamped to create a tamper-evident, audit-ready record. Without careful integration, such workflows can extend timelines, require additional site-level coordination and create friction for participants.

Controlled Flexibility and Accessibility

The recommended design approach is controlled flexibility: configure signature modalities by country, region or site to align with local regulatory expectations while preserving a unified participant experience, so participants review consent materials and complete required actions in a consistent, intuitive interface. Seamless transitions between document review and signature execution help minimize confusion and reduce the risk of incomplete or delayed consent.

Adaptability must be balanced with centralized oversight. All consent activities, regardless of modality, should be captured in a single system supporting real-time visibility, standardized audit trails and inspection readiness, so variability at the execution level does not produce fragmentation at the operational level. In this model, QES is deployed where required while lower-burden approaches remain available where appropriate.

Accessibility considerations reinforce the case for alternatives. Not all participants can complete identity verification associated with higher-assurance methods, due to lack of access to required identification documents, limited familiarity with digital tools, or constraints on connectivity and device availability. To ensure equitable access, alternative pathways must remain available, including hybrid models in which different documents within the same study use different signature modalities, or retained paper-based processes for specific populations or sites.

Building an Operational Capability

Successful global eConsent implementation extends beyond technology selection. Organizations that scale successfully typically begin with targeted deployments, validating workflows in specific regions before expanding more broadly. Standard operating procedures are developed to reflect modality differences, and site personnel are trained not only on system use but also on the decision frameworks that guide signature selection. Ongoing monitoring — maintaining visibility into consent workflows across sites and regions — allows sponsors to identify and address points of friction early, ensuring alignment with both regulatory expectations and participant needs.

The guidance also cautions against assuming quality assurance will catch signature configuration failures. Systems do not always bend neatly to country-specific rulesets, and if sites collect informed consent electronically in jurisdictions requiring QES, relying on QA to catch a misconfiguration is a dangerous assumption unless the workflow has been configured correctly from the outset. Even when QA does catch a misconfiguration, sponsors may never know it happened unless a process exists for surfacing and resolving those cases.

The overarching conclusion is that there is no universal e-signature strategy, and there should not be one. The goal is not to find the option with the highest compliance ceiling and apply it everywhere, but to match the right method to each country and population, document the reasoning, and give sites something they can follow under pressure. Sponsors who build that framework before the first participant comes in, the authors write, spend far less time reconstructing it under inspection later.